PolymarketKullanılabilirliği kontrol etKYC yok%2 ücretDoğrulanmış sonuçlanma verisiOrta düzey kalibre
Güncel ima edilen olasılık
December 31, 68%+1.0pt
Piyasa kalitesi
67 / 100
Orta kalite
24s Hacim
₺107,9 B
Likidite
₺951,5 B
Orta likidite
Alis / Satis
67.0% / 68.0%
Spread
1.0 pt
Dar spread
Comments
0
Piyasa verileri
15 dakika önce guncellendi
19 Ağu 26 17:4931 Ara 27 23:59
Trendler
Sonuç24sOlasılık
Kurallar
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET.
Otherwise, this market will resolve to "No".
Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
Differences in neoantigen composition between patients will not affect resolution.
Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above.
Approval as part of a combination regimen will qualify.
FDA approves skin cancer vaccine by which date? için güncel oranlar nedir?
Polymarket, 21 Ağustos 2026 itibarıyla December 31, için 68% fiyatlıyor.
FDA approves skin cancer vaccine by which date? ne zaman sonuçlanacak?
FDA approves skin cancer vaccine by which date? için öngörülen sonuçlanma tarihi 31 Aralık 2027.
FDA approves skin cancer vaccine by which date? nasıl sonuçlandırılıyor?
Polymarket bu piyasayı şu şekilde sonuçlandırır: This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET.